Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease

Konikoff MR, Denson LA, Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, concluded in their review in Inflamm Bowel Dis. 2006 Jun;12(6):524-34, that fecal calprotectin correlates well with histological inflammation as detected by colonoscopy with biopsies and has been shown successfully to predict relapses and detect pouchitis in patients with IBD

Fecal calprotectin has been shown to consistently differentiate IBD from irritable bowel syndrome because it has excellent negative predictive value in ruling out IBD in undiagnosed, symptomatic patients. Fecal calprotectin also may be useful in determining whether clinical symptoms in patients with known IBD are caused by disease flares or noninflammatory complications/underlying irritable bowel syndrome and in providing objective evidence of response to treatment. PMID: 16775498

CALPRO TEAM

General Information

Fecal calprotectin in differential diagnosis of irritable bowel syndrome

Li XG, Lv YM, Gu F, Yang XL., Department of Gastroenterology, Peking University Third May 9, 2015

Latest News

Calpro press release regarding MSD agreement

Please see the Calpro press release regarding MDS agreement for delivery of e-health technology CalproSmart:

Norsk | English October 13, 2016

Calprosmart in the Media

Please see our latest articles regarding CalproSmart in Aftenposten and LMF Norge

LMF Norge | Aftenposten October 12, 2016

View all latest

Share This